Elevated expression of activated forms of Neu/ErbB-2 and ErbB-3 are involved in the induction of mammary tumors in transgenic mice: implications for human breast cancer

被引:363
作者
Siegel, PM
Ryan, ED
Cardiff, RD
Muller, WJ [1 ]
机构
[1] McMaster Univ, Inst Mol Biol & Biotechnol, Hamilton, ON L8S 4K1, Canada
[2] McMaster Univ, Dept Biol, Hamilton, ON L8S 4K1, Canada
[3] McMaster Univ, Dept Pathol, Hamilton, ON L8S 4K1, Canada
[4] Univ Calif Davis, Sch Med, Dept Pathol, Davis, CA 95616 USA
关键词
activating mutations; ErbB receptors; mammary tumorigenesis; transgenic mice;
D O I
10.1093/emboj/18.8.2149
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
To assess the importance of Neu activation during mammary tumorigenesis, altered receptors harboring in-frame deletions within the extracellular domain were expressed in transgenic mice. Females from several independent lines develop multiple mammary tumors that frequently metastasize to the lung. Tumor progression in these strains was associated with elevated levels of tyrosine-phosphorylated Neu and ErbB-3, Consistent with these observations, a survey of primary human breast tumors revealed frequent co-expression of both erbB-2 and erbB-3 transcripts. The ability of altered Neu receptors to induce mammary tumorigenesis in transgenic mice prompted us to examine whether similar mutations occurred in ErbB-2 during human breast cancer progression. Interestingly, an alternatively spliced form of erbB-2, closely resembling spontaneous activated forms of neu, was detected in human breast tumors. The ErbB-2 receptor encoded by this novel transcript harbors an in-frame deletion of 16 amino acids in the extracellular domain and can transform Rat-1 fibroblasts. Together, these observations argue that co-expression of ErbB-2 and ErbB-3 may play a critical role in the induction of human breast tumors, and raise the possibility that activating mutations in the ErbB-2 receptor may also contribute to this process.
引用
收藏
页码:2149 / 2164
页数:16
相关论文
共 87 条
[1]   Disulfide bond structure of human epidermal growth factor receptor [J].
Abe, Y ;
Odaka, M ;
Inagaki, F ;
Lax, I ;
Schlessinger, J ;
Kohda, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1998, 273 (18) :11150-11157
[2]  
ALIMANDI M, 1995, ONCOGENE, V10, P1813
[3]   neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer [J].
Andrulis, IL ;
Bull, SB ;
Blackstein, ME ;
Sutherland, D ;
Mak, C ;
Sidlofsky, S ;
Pritzker, KPH ;
Hartwick, RW ;
Hanna, W ;
Lickley, L ;
Wilkinson, R ;
Qizilbash, A ;
Ambus, U ;
Lipa, M ;
Weizel, H ;
Katz, A ;
Baida, M ;
Mariz, S ;
Stoik, G ;
Dacamara, P ;
Strongitharm, D ;
Geddie, W ;
McCready, D .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1340-1349
[4]  
ASAI N, 1995, MOL CELL BIOL, V15, P1613
[5]  
BACUS SS, 1994, AM J CLIN PATHOL, V102, pS13
[6]   INCREASED TYROSINE KINASE-ACTIVITY ASSOCIATED WITH THE PROTEIN ENCODED BY THE ACTIVATED NEU ONCOGENE [J].
BARGMANN, CI ;
WEINBERG, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (15) :5394-5398
[7]   THE NEU ONCOGENE ENCODES AN EPIDERMAL GROWTH-FACTOR RECEPTOR-RELATED PROTEIN [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
NATURE, 1986, 319 (6050) :226-230
[8]   MULTIPLE INDEPENDENT ACTIVATIONS OF THE NEU ONCOGENE BY A POINT MUTATION ALTERING THE TRANSMEMBRANE DOMAIN OF P185 [J].
BARGMANN, CI ;
HUNG, MC ;
WEINBERG, RA .
CELL, 1986, 45 (05) :649-657
[9]  
Bodey B, 1997, ANTICANCER RES, V17, P1319
[10]   STOCHASTIC APPEARANCE OF MAMMARY-TUMORS IN TRANSGENIC MICE CARRYING THE MMTV/C-NEU ONCOGENE [J].
BOUCHARD, L ;
LAMARRE, L ;
TREMBLAY, PJ ;
JOLICOEUR, P .
CELL, 1989, 57 (06) :931-936